tbuckley/cabot-search huggingface dataset:
BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation
Authors: M.M. Wasylecka-Juszczyńska, P. Górniak, M. Szydłowski, A. Polak, P. Juszczyński
Journal: Annals of Oncology (2018)
Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Authors: T. Kawakami, K. Yamazaki, E. Oki, M. Shimokawa, N. Takahashi, M. Yokota, S. Tokunaga, T. Esaki, M. Gamoh, A. Maeda, Y. Tsuji, A. Sakai, K. Hatanaka, Y. Shimada, M. Shiozawa, Y. Komatsu, H. Okuda, M. Ohue, Y. Maehara
Journal: Annals of Oncology (2018)
MA26.07 ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists
Authors: A. Hanlon Newell, W. Liu, L. Bubendorf, R. Büttner, K. Kerr, M. Kockx, M. Kossai, F. Lopez-Rios, A. Marchetti, I. Marondel, A. Nicholson, B. Oz, P. Pauwels, F. Penault-Llorca, G. Rossi, V. Rüsseler, E. Thunnissen, G. Pate, B. Portier, C. Faure, C. Le, D. Smith, I. Menzl, R. Huang
Journal: Journal of Thoracic Oncology (2018)
Abstract 14850: Heme Oxygenase-1 (HO-1) Promotes c-Kit+ Cardiac Stem Cell Migration via the SDF-1a-CXCR4 Signaling Pathway
Authors: Qianhong Li, Qinghui Ou, Li Luo, Yun Zhou, Aruni Bhatnagar, Steven P Jones, Sumanth D Prabhu, Yiru Guo, Roberto Bolli
Journal: Circulation (2013)

We have previously reported that HO-1 enhances the cardiac reparative actions of Lin-/c-kit+ cardiac stem cells (CSCs) in the setting of LV dysfunction and remodeling after myocardial infarction (M...
Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non-small cell lung cancer
Authors: G. Galli, M. Poggi, G. Fucà, G. Lo Russo, C. Proto, D. Signorelli, M. Vitali, M. Ganzinelli, N. Zilembo, F. de Braud, M.C. Garassino, M. Imbimbo
Journal: Annals of Oncology (2018)

Background: Immunotherapy (IO) is an established treatment (tx) option for metastatic non-small cell lung cancer (mNSCLC). Nonetheless, as only a minority of pts shows tumor response, research is focusing on identification of predictive factors to improve pts' selection. The potential role of blood cell count alterations has been proposed, but evidence is contradictory. We aimed at studying the role of lymphopenia in a cohort of mNSCLC pts treated with IO. Methods: We retrospectively collected data about all mNSCLC pts treated with IO at Istituto Nazionale dei Tumori, Milan, Italy, from 04/2013 to 01/2018. Basal lymphopenia (Lp) was defined as a lymphocyte count (LC)≤900/mL at the first administration of IO and was considered as a categorical variable. Survival was estimated with Kaplan-Meier method; log-rank test was used to compare curves. Multivariate analyses were performed with Cox proportional model. Results: We identified 150 pts, with a median age of 66.5 years. IO was an antiPD1 in 64.0% of cases, an antiPDL1 in 31.3% of cases, and a combination antiPDL1/CTLA4 in 4.7% of cases. IO was administered as a first line tx in 23 pts, as a second line tx in 66 cases, as a more advanced line of tx in 61 cases. Median progression free survival (PFS) and overall survival (OS) of the global population were 3.2 and 11.2 months (mos), respectively. Though non-statistically significant, there was a tendency towards a lower response rate (RR) for cases with basal Lp (10.0% vs 25.0%, p.0881); disease control rate (DCR) for the same group was significantly worse (30.0% vs 58.4%, p.0074) than for cases without Lp. Pts with Lp also showed shorter PFS and OS than cases with normal LC (PFS 1.9 vs 3.0 mos, p.0010; OS 4.5 vs 13.5 mos, p<.0001). The impact of LC on OS retained significance after correction for the effects of performance status, which was the only other variable influencing this endpoint. Conclusions: The presence of Lp at the beginning of IO was related to inferior disease control and shorter survival in the analyzed cohort. Given the limitations of a retrospective study, these results need confirmation in larger case series. Nonetheless, the suggestion that Lp may predict poor benefit from IO in mNSCLC warrants further investigation. Legal entity responsible for the study: Istituto Nazionale dei Tumori. Funding: Has not received any funding. Disclosure: G. Lo Russo: Honoraria: Eli Lilly, BMS, AstraZeneca. C. Proto: Honoraria: BMS, MSD, Eli Lilly. D. Signorelli: Honoraria: AstraZeneca, Boehringer Ingelheim, BMS. M.C. Garassino: Honoraria: Boehringer Ingelheim, AstraZeneca, Roche. M. Imbimbo: Honoraria: BMS. All other authors have declared no conflicts of interest.
Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma
Authors: Etienne Giroux-Leprieur, Coraline Dumenil, Thierry Chinet
Journal: Journal of Thoracic Oncology (2018)
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma
Authors: Bimal Bhindi, E. Jason Abel, Laurence Albiges, Karim Bensalah, Stephen A. Boorjian, Siamak Daneshmand, Jose A. Karam, Ross J. Mason, Thomas Powles, Axel Bex
Journal: European Urology (2018)
Comparison of PARPi with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: A network meta-analysis
Authors: Y.L. Feng, J.H. Liu, H. Huang, C. Zhang, T. Wan, C.J. Tong, T. Deng, H. Tu, Y.W. Huang, G. Liu, Q.D. Huang, Z.M. Liu
Journal: Annals of Oncology (2018)
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial
Authors: C. Yoo, D.-Y. Oh, H.J. Choi, M. Kudo, M. Ueno, S. Kondo, L.-T. Chen, M. Osada, C. Helwig, I. Dussault, M. Ikeda
Journal: Annals of Oncology (2018)
P1.01-93 Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+
Authors: D. Talbot, R. Govindan, M. Cobo, S. Ponce Aix, P.E. Postmus, C. Lewanski, J. Bennouna, J. Fischer, O. Juan-Vidal, D. Stewart, A. Ardizzoni, R. Bhore, M. Wolfsteiner, M. Reck, D. Morgensztern, T.J. Ong
Journal: Journal of Thoracic Oncology (2018)
Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)
Authors: P. Gajate Borau, A. Martin Marino, I. Gallegos Sancho, J.C. Villa Guzman, A. Velastegui, T. Alonso Gordoa, D. Castellano, G. Rubio Romero, A. Pinto Marin, L. Villalobos Leon, C. Maximiano Alonso, M.J. Sotelo-Lezama, M. Sereno Moyano, J.F. Rodríguez, C. Perezagua Marin, J. Ballesteros, D. Marrupe Gonzalez, L. Rodriguez Lajusticia, J.J. Tafalla García, C. Aguado
Journal: Annals of Oncology (2018)

Background: Addition of D to ADT increased overall survival in high volume disease mHSPC. Nevertheless, there is a lack of information about the management after disease progression and predictive factors of efficacy for subsequent therapies are unknown. Methods: Retrospective analysis of 163 mHSPC patients (pt) treated with D in 23 Spanish Centers from July 2014 to April 2018. Objectives of the study are: describe baseline and progression characteristics, treatment choices and efficacy outcomes of subsequent therapies based on pretreatment features. Results: After a median follow up of 18.04 months (m), 93 pt (57.1%) developed CRPC. Median time to CRPC was 15.97 m (CI 95%: 10.97 m – 28.16 m). 80 pt received subsequent treatment after progression: 23 (28.8%) received chemotherapy (CT) (3 D, 17 cabazitaxel, 3 carboplatin-etoposide), 52 (65%) androgen receptor axis-targeted agents (31 enzalutamide, 21 abiraterone) and 5 radium-223. Baseline characteristics of pt at CRPC disease were: median age: 67.1 year; median PSA doubling time (PSADT): 2 m, and median PSA, Hemoglobin (Hb), LDH and alkaline phosphatase (alk-P) was 20.3 ng/mL, 12.95 g/dL, 326 UI/mL and 144 UI/mL, respectively. 26.4% of pt had visceral progression. Median progression free survival (PFS) of pt in first-line treatment for mCRPC was 6.93 m (CI95%: 3.58-10.02). In univariate analysis, hormonal therapy showed a significant longer PFS compared to CT (7.49 m vs 6.27 m; HR 0.55; p 0.048), but no association was found after adjustment by other prognostic characteristics (HR 0.77; p 0.79). Although no significant association was observed in multivariate analysis, pt with more aggressive clinical characteristics achieved a longer PFS with CT (Table).Table: 823PPFS at first-line treatment of mCRPCHT (m)CT (m)pPSADT < 3 m PSADT > = 3 m4.46 9.396.27 3.590.6 0.07Visceral PD Non Visceral PD4.33 5.955.59 3.540.59 0.12LDH H LDH L4.34 12.05.59 8.210.29 0.3Hb H Hb LNR 4.05.58 6.270.03 0.63alk-P H alk-P L3.81 11.996.93 5.520.94 0.03PSA H PSA L3.81 8.545.52 5.580.35 0.14 Open table in a new tab Conclusions: Baseline characteristics at CRPC disease could help us to identify the best therapy option for pt pretreated with D + ADT in mHSPC. Our analyses suggest that CT could benefit pt with more aggressive clinical features. Legal entity responsible for the study: Pablo Gajate Borau. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma
Authors: Liran Zhou, Hongmei Husted, Todd Moore, Mason Lu, Defeng Deng, Yan Liu, Vijaya Ramachandran, Thiruvengadam Arumugam, Christof Niehrs, Huamin Wang, Paul Chiao, Jianhua Ling, Michael A. Curran, Anirban Maitra, Mien-Chie Hung, Jeffrey E. Lee, Craig D. Logsdon, Rosa F. Hwang
Journal: Science Translational Medicine (2018)

DKK3 is produced by the stroma in pancreatic cancer, promotes tumor progression and resistance to therapy, and is a therapeutic target.
Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): Post hoc analysis of the MOSAIC trial
Authors: E. Auclin, T. Andre, J. Taieb, M. Banzi, J.-L. van Laethem, J. Tabernero, T. Hickish, A. de Gramont, D. Vernerey
Journal: Annals of Oncology (2018)
P1.13-16 The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis
Authors: F. Passiglia, M. Di Maio, S. Rizzo, A. Galvano, G. Badalamenti, A. Listì, N. Barraco, L. Incorvaia, M. Castiglia, V. Bazan, A. Russo
Journal: Journal of Thoracic Oncology (2018)
Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany
Authors: W.M. Brueckl, E. Laack, M. Reck, F. Griesinger, H. Schäfer, C. Kortsik, T. Gaska, J. Rawluk, S. Krüger, K. Kokowski, S. Budweiser, A. Schueler, S. Kiessling
Journal: Annals of Oncology (2018)
Patient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA)
Authors: R. Morlock, M.R. Krukas-Hampel, Ö Türeci
Journal: Annals of Oncology (2018)
P1.14-20 The Expression of DNA Methylation of GAD1 Gene is an Indicator of Malignant Behavior in Thymic Epithelial Tumor
Authors: K. Kondo, S. Soejima, N. Wusiman, R. Kishibuchi, M. Tsuboi, K. Kajiura, Y. Kawakami, N. Kawakita, T. Sawada, H. Toba, M. Yoshida, H. Takizawa, A. Tangoku
Journal: Journal of Thoracic Oncology (2018)
NHS in Scotland is “not financially sustainable,” auditors warn
Authors: Bryan Christie
Journal: BMJ (2018)

A stark warning has been issued about the future of the health service in Scotland in a critical report that says it is not financially sustainable in its current form.

Audit Scotland has performed its annual health check on the service and found a continuing decline in performance, longer waiting times for patients, major workforce challenges, and increasing difficulty among health boards to deliver services within existing budgets.1

Only one of the eight key national performance targets was met in Scotland in 2017-18 (for patients with drug and alcohol issues to …
Correction to: White paper: statement on conflicts of interest (Intensive Care Medicine, (2018), 10.1007/s00134-018-5349-8)
Authors: J Bion, M Antonelli, L Blanch, J Curtis, C Druml, B Du, F Machado, C Gomersall, C Hartog, M Levy, J Myburgh, G Rubenfeld, C Sprung
Journal: Intensive Care Medicine (2018)
AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Authors: C. Cardone, B. Blauensteiner, V. Moreno-Viedma, M.C. Paul, G. Martini, P.P. Vitiello, D. Ciardiello, C. Borrelli, L. Poliero, P. Vitale, N. Zanaletti, V. Famiglietti, A.M. Rachiglio, D. Rizzi, E. Maiello, T.P. Latiano, N. Normanno, M. Sibilia, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2018)
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled <scp>TRANSFIGURE</scp> trial
Authors: K. Reich, J. Sullivan, P. Arenberger, U. Mrowietz, S. Jazayeri, M. Augustin, A. Parneix, P. Regnault, R. You, M. Milutinovic
Journal: British Journal of Dermatology (2018)

Nail psoriasis is associated with functional impairment, pain and reduced quality of life. To demonstrate the superiority of secukinumab over placebo in clearing nail psoriasis as assessed by the Nail Psoriasis Severity Index (NAPSI) at week 16 and over time up to week 132. Presented here is the week 32 interim analysis. Impact on quality of life was assessed by Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) patient questionnaires. TRANSFIGURE is a double‐blind, randomized, placebo‐controlled study in patients with moderate‐to‐severe plaque and nail psoriasis. The primary objective of this study was met: both doses of secukinumab were superior to placebo at week 16 (NAPSI improvements of −45·3%, −37·9% and −10·8% for secukinumab 300 mg and 150 mg and placebo, respectively, P < 0·001). Significant improvements were seen in patients' quality of life: the NAPPA‐Quality of Life total score median decreases at week 16 were 60·9%, 49·9% and 15·8% for secukinumab 300 mg and 150 mg and placebo, respectively (P < 0·001). Improvement in nail psoriasis continued to week 32: NAPSI percentage change reached −63·2% and −52·6% for secukinumab 300 mg and 150 mg, respectively. Skin clearance measured by ≥ 90% improvement in Psoriasis Area and Severity Index was significant (rates of 72·5%, 54·0% and 1·7% for secukinumab 300 mg and 150 mg and placebo at week 16, respectively, P < 0·001) and was sustained to week 32. The most common adverse events were nasopharyngitis, headache and upper respiratory tract infections. Secukinumab demonstrated significant and clinically meaningful efficacy and quality‐of‐life improvements for patients with nail psoriasis up to week 32. What's already known about this topic? Nail psoriasis is understudied and there is a lack of effective treatment options. Nail psoriasis is correlated with more severe psoriatic disease and the development of psoriatic arthritis. What does this study add? TRANSFIGURE is one of the few prospective placebo‐controlled trials specifically in nail psoriasis and includes nail‐specific quality‐of‐life measures such as Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA)‐Quality of Life and NAPPA‐Patient Benefit Index. In this trial, secukinumab demonstrates significant efficacy and quality‐of‐life improvements in this difficult‐to‐treat population.
P3.01-87 Efficacy and Safety of Pembrolizumab in Non-Small Cell Lung Cancer in Our Institution: A Retrospective Study
Authors: N. Saijo, Y. Inagaki, Y. Abe, S. Kono, Y. Taniguchi, K. Otsuka, Y. Naoki, A. Tamiya, K. Okishio, S. Atagi
Journal: Journal of Thoracic Oncology (2018)
P1.14-10 Surgical Treatment of a Rare Case of Clear Cell Carcinomatous Transformation of a Diaphragmatic Endometriosis Focus
Authors: A. De Palma, M. Lorusso, R. Quercia, O. Pizzuto, G. Garofalo, A. Fiorella, E. Maiolino, G. Nex, M. Schiavone, G. De Iaco, G. Serio
Journal: Journal of Thoracic Oncology (2018)
Can concomitant diseases predict the compliance with cisplatin plus RT in patients with LA SCCHN? An exploratory endpoint analysis of the COMPLY trial
Authors: J. Dunst, G. Hildebrandt, M. Becker-Schiebe, T. Kuhnt, F. Weykamp, F. Martucci, D. Vordermark, M. Pless, D. Hofmann, V. Bühler, S.I. Rothschild
Journal: Annals of Oncology (2018)
Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction
Authors: William R. Zhang, Timothy E. Craven, Rakesh Malhotra, Alfred K. Cheung, Michel Chonchol, Paul Drawz, Mark J. Sarnak, Chirag R. Parikh, Michael G. Shlipak, Joachim H. Ix
Journal: Annals of Internal Medicine (2018)

Background: Whether the increased incidence of chronic kidney disease (CKD) during intensive systolic blood pressure (SBP) lowering is accompanied by intrinsic kidney injury is unknown. Objective: To compare changes in kidney damage biomarkers between incident CKD case participants and matched control participants as well as between case participants in the intensive (<120 mm Hg) versus the standard (<140 mm Hg) SBP management groups of SPRINT (Systolic Blood Pressure Intervention Trial). Design: Nested case–control study within SPRINT. Setting: Adults with hypertension without baseline kidney disease. Participants: Case participants (n = 162), who developed incident CKD during trial follow-up (128 in the intensive and 34 in the standard group), and control participants (n = 162) without incident CKD, who were matched on age, sex, race, baseline estimated glomerular filtration rate, and randomization group. Measurements: 9 urinary biomarkers of kidney damage were measured at baseline and at 1 year. Linear mixed-effects models were used to estimate 1-year biomarker changes. Results: Higher concentrations of urinary albumin, kidney injury molecule-1, and monocyte chemoattractant protein-1 at baseline were significantly associated with greater odds of incident CKD (adjusted odds ratio per doubling: 1.50 [95% CI, 1.14 to 1.98], 1.51 [CI, 1.05 to 2.17], and 1.70 [CI, 1.13 to 2.56], respectively). After 1 year of blood pressure intervention, incident CKD case participants in the intensive group had significantly greater decreases in albumin–creatinine ratio (ACR), interleukin-18, anti–chitinase-3-like protein 1 (YKL-40), and uromodulin than the matched control participants. Compared with case participants in the standard group, those in the intensive group had significantly greater decreases in ACR, β2-microglobulin, α1-microglobulin, YKL-40, and uromodulin. Limitation: Biomarker measurements were available only at baseline and 1 year. Conclusion: Incident CKD in the setting of intensive SBP lowering was accompanied by decreases, rather than elevations, in levels of kidney damage biomarkers and thus may reflect benign changes in renal blood flow rather than intrinsic injury. Primary Funding Source: National Institute for Diabetes and Digestive and Kidney Diseases.
MA04.01 Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts
Authors: V. Moreno, M. Gil-Martin, M. Johnson, R. Aljumaily, M.P. Lopez-Criado, D. Northfelt, M. Crittenden, S. Jabbour, L. Rosen, E. Calvo, K. Papadopoulos, P. Garrido, A. Hervás Morón, P. Rietschel, K. Mohan, J. Li, E. Stankevich, M. Feng, I. Lowy, M. Fury
Journal: Journal of Thoracic Oncology (2018)
Evaluation of Lightmix Mycoplasma macrolide assay for detection of macrolide-resistant Mycoplasma pneumoniae in pneumonia patients
Authors: K. Wagner, F. Imkamp, V.P. Pires, P.M. Keller
Journal: Clinical Microbiology and Infection (2018)

ObjectivesRapid detection of macrolide resistance–associated mutations in Mycoplasma pneumoniae is crucial for effective antimicrobial treatment. We evaluated the Lightmix Mycoplasma macrolide assay for the detection of point mutations at nucleotide positions 2063 and 2064 in the 23S ribosomal RNA (rRNA) gene of M. pneumoniae that confer macrolide resistance.MethodsSamples from 3438 patients with a respiratory tract infection were analysed by M. pneumoniae real-time PCR, and 208 (6%) of them were tested positive. In this retrospective study, 163 M. pneumoniae real-time PCR–positive samples were analysed by the Lightmix assay, and results were compared to targeted 23S rRNA sequencing.ResultsMacrolide-resistant M. pneumoniae were found in 15 (9%) of 163 retrospectively analysed samples. The Lightmix assay showed a sensitivity of 100% (95% confidence interval, 78.2–100) and a specificity of 100% (95% confidence interval, 97.5–100) as the detected M. pneumoniae genotype (148 wild type and 15 non–wild type) was confirmed by 23S rRNA sequencing in all samples.ConclusionsThe Lightmix assay is an easy-to-use and accurate molecular test that allows rapid determination of macrolide resistance in M. pneumoniae.
Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Authors: D.Y. Lee, S.E. Park, C. Cha, C.-I. Yoon, S.J. Bae, S.G. Ahn, J. Jeong
Journal: Annals of Oncology (2018)
MA05.10 The Pathologic Response of Locally Advanced NSCLC Treated with Concomitant Chemoradiation to 60 Gy in Image Guided Radiation Therapy (IGRT)
Authors: S. Appel, J. Bar, D. Urban, A. Onn, M. Perelman, Y. Lawrence, A. Ben-Nun, O. Haisraely, Z. Symon, T. Rabin El Ezra, E. Marom, S. Liberman, E. Ofek
Journal: Journal of Thoracic Oncology (2018)
KRAS mutations as a prognostic factor after metastasectomy in colorectal cancer patients
Authors: M. Domenech Viñolas, C. Santos, J. Pérez, M. Varela, M. Martinez Villacampa, A. Teule, J.C. Ruffinelli Rodriguez, N. Mulet Margalef, G. Soler, A. Ortega, M.S. Bergamino, X. SanJuan, J. Torras, E. Ramos, R. Salazar
Journal: Annals of Oncology (2018)
Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI)
Authors: L. Hendriks, C. Henon, E. Auclin, L. Mezquita, R. Ferrara, C. Audigier Valette, J. Mazieres, C. Lefebvre, S. Le Moulec, B. Duchemann, C. Le Pechoux, A. Botticella, S. Ammari, A. Gazzah, C. Caramella, J. Adam, D. Planchard, D. De Ruysscher, A.-M.C. Dingemans, B. Besse
Journal: Annals of Oncology (2018)
P1.09-20 Correlation Between Whole Genomic Copy Number Variant Scoring and Pathological Classification, Staging in Lung Non-Mucinous Adenocarcinoma
Authors: Z. Wang, D. Liu, S. Li, L. Zhang, S. He, J. Du, J. Di, M. Zhang, Y. Gong, B. Liu, X. Li, W. Wu, D. Cram
Journal: Journal of Thoracic Oncology (2018)
ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
Authors: D. Tripathy, S.M. Tolaney, A.D. Seidman, C.K. Anders, N.K. Ibrahim, H.S. Rugo, C.J. Twelves, V. Dieras, V. Müller, A.L. Hannah, M.A. Tagliaferri, J. Cortes Castan
Journal: Annals of Oncology (2018)